Entity

Time filter

Source Type

Fujisawa, Japan

Maeda A.,Yokohama City University | Tamura K.,Yokohama City University | Wakui H.,Yokohama City University | Ohsawa M.,Yokohama City University | And 10 more authors.
BioMed Research International | Year: 2014

In the present study, we examined the therapeutic effects of olmesartan, an angiotensin II (Ang II) type 1 receptor (AT1R)-specific blocker, in genetically obese diabetic KKAy mice, a model of human metabolic disorders with visceral obesity, with a focus on an olmesartan effect on the adipose tissue. Olmesartan treatment (3 mg/kg per day) for 4 weeks significantly lowered systolic blood pressure but did not affect body weight during the study period in KKAy mice. However, there were three interesting findings possibly related to the pleiotropic effects of olmesartan on adipose tissue in KKAy mice: (1) an inhibitory effect on adipocyte hypertrophy, (2) a suppressive effect on IL-6 gene expression, and (3) an ameliorating effect on oxidative stress. On the other hand, olmesartan exerted no evident influence on the adipose tissue expression of AT1R-associated protein (ATRAP), which is a molecule interacting with AT1R so as to inhibit pathological AT1R activation and is suggested to be an emerging molecular target in metabolic disorders with visceral obesity. Collectively, these results suggest that the blood pressure lowering effect of olmesartan in KKAy mice is associated with an improvement in adipocyte, including suppression of adipocyte hypertrophy and inhibition of the adipose IL-6-oxidative stress axis. Further study is needed to clarify the functional role of adipose ATRAP in the pleiotropic effects of olmesartan. © 2014 Akinobu Maeda et al. Source


Nagashima M.,Kyosai Yokohama Minami Hospital | Sekiguchi Z.,Kyosai Yokohama Minami Hospital | Muraoka K.,Kyosai Yokohama Minami Hospital | Osada Y.,Kyosai Yokohama Minami Hospital | Kitami K.,Fujisawa Municipal Hospital
Japanese Journal of Clinical Urology | Year: 2011

We retrospectively analyzed 166 patients with newly diagnosed stage D prostate cancer who had been treated in our hospital between 1987 and 2007 to evaluate factor of prognosis. Their mean age was 71.48 (50-91) years with median follow up of 30.8 (l-119) months. There were differences in over all survival and disease specific survival depending on gleason score and the time to hormone refractory prostate cancer. Differences were also found in biochemical failure-free rate, over all survival and disease specific survival depending whether or not PSA nadir level at least 4.0 or less was attained after androgen deprivation therapy. A significant difference was calculated in overall survival between chemotherapy (IFAP or CAP) performed and without chemothrapy. This result suggests systemic androgen deprivation chemotherapy in proves prognosis of stage D prostate cancer. Source


Azushima K.,Yokohama City University | Tamura K.,Yokohama City University | Haku S.,Yokohama City University | Wakui H.,Yokohama City University | And 21 more authors.
Atherosclerosis | Year: 2015

There is no clinical evidence that supports the benefit of integrative medicine, defined as combination therapy of oriental and western medicine, on obesity-related hypertension. This study evaluates the efficacy of Bofu-tsusho-san (BOF), an oriental herbal medicine, on the ambulatory blood pressure (BP) profile in hypertensive patients with obesity. Methods: The study design was a multicenter, randomized, open-label, parallel-group controlled trial in 107 hypertensive patients with obesity. Participants were randomly assigned to receive either the conventional control therapy or BOF add-on therapy. In both groups antihypertensive therapy was aimed at achieving the target clinic BP. The primary outcome was change in the ambulatory BP profile from baseline to 24 weeks after randomization. Results: Daytime systolic BP variability, an important parameter of ambulatory BP profile, was decreased in the BOF group, and the difference in the changes in daytime systolic BP variability was significant between the BOF and control group (Control vs BOF; the change from baseline in daytime systolic BP variability, 1.0±3.3 vs-1.0±3.3%; p=0.006). Conclusion: The BOF add-on therapy effectively improved the ambulatory BP variability. This is the first report suggesting that an integrative medicine approach may exert favorable effects on obesity-related hypertension compared with conventional pharmaceutical treatment. Clinical trial registration: UMIN000003878. © 2015 The Authors. Source


Tamura K.,Yokohama City University | Tsurumi-Ikeya Y.,Yokohama City University | Wakui H.,Yokohama City University | Maeda A.,Yokohama City University | And 12 more authors.
Therapeutic Apheresis and Dialysis | Year: 2013

Cardiovascular disease (CVD) is a major cause of death in patients with chronic kidney disease (CKD). Patients with CKD are reported to have a significant greater risk of CVD-associated mortality than that of the general population after stratification for age, gender, race, and the presence or absence of diabetes. CKD itself is also an independent risk factor for the development of atherosclerosis, and in particular, patients undergoing dialysis typically bear many of the risk factors for atherosclerosis, such as hypertension, dyslipidemia and disturbed calcium-phosphate metabolism, and commonly suffer from severe atherosclerosis, including peripheral arterial disease (PAD). Low-density lipoprotein (LDL) apheresis is a potentially valuable treatment applied to conventional therapy-resistant hypercholesterolemic patients with coronary artery disease and PAD. Although previous and recent studies have suggested that LDL apheresis exerts beneficial effects on the peripheral circulation in dialysis patients suffering from PAD, probably through a reduction of not only serum lipids but also of inflammatory or coagulatory factors and oxidative stress, the precise molecular mechanisms underlying the long-term effects of LDL apheresis on the improvement of the peripheral circulation remains unclear and warrants further investigation. © 2012 International Society for Apheresis. Source


Iizuka Y.,Toho University | Koda E.,Toho University | Tsutsumi Y.,National Center for Child Health and Development | Konishi Y.,Kyorin University | And 2 more authors.
Neuroradiology Journal | Year: 2013

A male neonate presented a dural arteriovenous fistula (DAVF) at the confluence with paralysis of the orbicularis oris muscle. The interesting features in our case were the clinical symptoms (orbicularis oris muscle paralysis at birth), angioarchitecture (high-flow arteriovenous shunts at the confluence) and the size and hemodynamic flow (mid-sized venous pouch) of the fistula. Additionally, the embolization technique (i.e., occipital artery approach, closing shunts with pure glue) automatically resulted in the immediate and complete closure of accessory feeders without any additional treatment, and the midterm clinical outcome was good. We succeeded improving the symptoms of a neonate with a congenital high-flow DAVF by closing a fistula using a small amount of glue. Source

Discover hidden collaborations